Stockscreener 앱 받기
26.00
1.70%
-0.45
시간 외 거래:
26.04
0.04
+0.15%
전일 마감가:
$26.45
열려 있는:
$26.2
하루 거래량:
1.83M
Relative Volume:
1.07
시가총액:
$5.24B
수익:
-
순이익/손실:
$-382.71M
주가수익비율:
-9.9237
EPS:
-2.62
순현금흐름:
$-325.64M
1주 성능:
-0.04%
1개월 성능:
+2.56%
6개월 성능:
+56.44%
1년 성능:
+17.81%
1일 변동 폭
$25.42
$26.42
1주일 범위
$25.42
$27.44
52주 변동 폭
$12.72
$27.80
Immunovant Inc Stock (IMVT) Company Profile
명칭
Immunovant Inc
전화
917-580-3099
주소
320 WEST 37TH STREET, NEW YORK, NY
IMVT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
26.00 | 5.33B | 0 | -382.71M | -325.64M | -2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.90 | 120.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.45 | 78.77B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
840.50 | 52.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
338.06 | 45.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.38 | 38.73B | 4.98B | 69.59M | 525.67M | 0.5197 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-06 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-10-14 | 개시 | Truist | Hold |
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-03-03 | 개시 | Jefferies | Hold |
| 2025-01-03 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-10-09 | 재확인 | Oppenheimer | Outperform |
| 2024-03-28 | 개시 | Oppenheimer | Outperform |
| 2024-03-13 | 개시 | Goldman | Buy |
| 2024-02-20 | 개시 | JP Morgan | Overweight |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-13 | 업그레이드 | UBS | Neutral → Buy |
| 2023-09-26 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | 개시 | BofA Securities | Buy |
| 2023-04-25 | 개시 | Citigroup | Buy |
| 2023-03-31 | 개시 | Piper Sandler | Overweight |
| 2023-03-30 | 개시 | Stifel | Buy |
| 2023-02-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-13 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-01-03 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-12-08 | 개시 | Wells Fargo | Equal Weight |
| 2021-08-03 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-06-01 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-10-12 | 개시 | Guggenheim | Buy |
| 2020-10-08 | 개시 | Stifel | Buy |
| 2020-10-02 | 개시 | Credit Suisse | Outperform |
| 2020-08-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-07-29 | 개시 | H.C. Wainwright | Buy |
| 2020-02-24 | 개시 | SVB Leerink | Outperform |
모두보기
Immunovant Inc 주식(IMVT)의 최신 뉴스
Immunovant (IMVT) Expected to Post Quarterly Earnings on Friday - MarketBeat
Breakout Zone: What are analysts price targets for Immunovant Inc2025 Volume Leaders & Weekly Top Stock Performers List - baoquankhu1.vn
Immunovant, Inc. (IMVT) Stock Analysis: Exploring a 51.55% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Investors Purchase High Volume of Call Options on Immunovant (NASDAQ:IMVT) - MarketBeat
Published on: 2026-01-26 14:49:08 - baoquankhu1.vn
Apellis, Olema, Exicure, Immunovant, LivePerson Insider Shake-Up - TipRanks
Immunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The Fence - MSN
Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 - The Manila Times
Immunovant (NASDAQ:IMVT) CTO Jay Stout Sells 1,977 Shares - MarketBeat
(IMVT) Volatility Zones as Tactical Triggers - Stock Traders Daily
Immunovant, Inc. (NASDAQ:IMVT) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Immunovant, Inc. (IMVT) Stock Analysis: A Biotech Marvel With 53% Potential Upside - DirectorsTalk Interviews
SG Americas Securities LLC Has $1.01 Million Stock Holdings in Immunovant, Inc. $IMVT - MarketBeat
Merger Talk: What are Immunovant Incs earnings expectationsTrade Risk Report & Precise Buy Zone Tips - baoquankhu1.vn
Assessing Immunovant (IMVT) Valuation After Strong 90 Day Share Price Momentum - Yahoo Finance
How Much Upside is Left in Immunovant (IMVT)? Wall Street Analysts Think 47.39% - Finviz
Immunovant (NASDAQ:IMVT) Stock Price Down 5.7%Should You Sell? - MarketBeat
Portfolio Update: Is Immunovant Inc stock gaining market share2025 Year in Review & Capital Efficient Trade Techniques - Bộ Nội Vụ
Truist lifts Immunovant (IMVT) PT to $22 on updated 2026 financial modeling - MSN
Truist Lifts Immunovant (IMVT) PT to $22 on Updated 2026 Financial Modeling - Insider Monkey
Sjogren’s Syndrome Market to Experience Notable Growth in Forecast Span by 2034, DelveInsight Predicts | Astellas Pharma, Immunovant Sciences, NK Cells Artiva Biotherapeutics, Rise Therapeutics - Barchart.com
Price-Driven Insight from (IMVT) for Rule-Based Strategy - Stock Traders Daily
10 Promising Stocks to Buy Under $50 - Insider Monkey
Immunovant announces $550 million stock offering - MSN
Immunovant CTO Stout sells $32k in IMVT stock By Investing.com - Investing.com Australia
Immunovant CTO Stout sells $32k in IMVT stock - Investing.com
Immunovant (NASDAQ:IMVT) CTO Jay Stout Sells 1,203 Shares - MarketBeat
Immunovant (NASDAQ:IMVT) Reaches New 52-Week High on Analyst Upgrade - MarketBeat
Immunovant stock hits 52-week high at $27.71 By Investing.com - Investing.com India
Immunovant stock hits 52-week high at $27.71 - Investing.com
Market Recap: Can Immunovant Inc. stock maintain operating marginsWeekly Investment Summary & Real-Time Market Sentiment Alerts - Улправда
How Immunovant Inc. stock compares to industry benchmarksJuly 2025 Gainers & Smart Swing Trading Alerts - Улправда
How Immunovant Inc. stock performs in stagflationPortfolio Risk Report & Precise Trade Entry Recommendations - ulpravda.ru
What technical charts say about Immunovant Inc. stockWeekly Risk Summary & Free Fast Gain Swing Trade Alerts - ulpravda.ru
Immunovant (NASDAQ:IMVT) Price Target Raised to $22.00 at Truist Financial - MarketBeat
Wolfe Research upgrades Immunovant stock to Outperform on Graves’ disease potential By Investing.com - Investing.com South Africa
Wolfe Research Upgrades Immunovant (IMVT) - Nasdaq
Wolfe Research upgrades Immunovant stock to Outperform on Graves’ disease potential - Investing.com Nigeria
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT) - PR Newswire
Immunovant CEO Peter Salzmann sells $208,899 in stock - MSN
Wolfe Research Downgrades Immunovant (IMVT) - MSN
(IMVT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Immunovant (NASDAQ:IMVT) Nasdaq Today Immunology Innovation - Kalkine Media
Immunovant, Inc. (NASDAQ:IMVT) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
How Investors Are Reacting To Immunovant (IMVT) $550 Million Follow-On Equity Raise And Dilution - Sahm
Assenagon Asset Management S.A. Invests $3.31 Million in Immunovant, Inc. $IMVT - MarketBeat
Research Analysts Issue Forecasts for Immunovant Q3 Earnings - MarketBeat
Immunovant Inc (IMVT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.27%
자본화:
|
볼륨(24시간):